drugset / Trial / NCT03358355
Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial
NaSingle-groupOpen-labelTreatment
Summary
The GIFT pilot study will investigate the optimal subcutaneous dose and safety of subcutaneously administered unacylated ghrelin in older people with peripheral artery disease (PAD).
Timeline
- Start
- 2016-06-07
- Primary completion
- 2017-08-30
- Completion
- 2017-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ghrelin | Peptide | 10 ug/kg | Subcutaneous |
| Subject | Ghrelin | Peptide | 20 ug/kg | Subcutaneous |
| Subject | Ghrelin | Peptide | 40 ug/kg | Subcutaneous |